Axelar AB welcomes Vidar Wendel-Hansen as Chief Medical Officer
Vidar Wendel-Hansen has more than twenty years’ experience from pre-clinical and clinical development. He has served as Medical Director in both small biotech and large pharmaceutical companies. Dr Wendel-Hansen is also former Clinical Assessor at the Swedish Medical Products Agency. Vidar Wendel-Hansen, born in 1959, received both an MD and PhD degree from Karolinska Institutet. He will work on a part-time consultancy basis.
“We are delighted to have been able to recruit Vidar Wendel-Hansen as CMO at Axelar AB. His extensive experience of both pre-clinical and clinical drug development will be extremely valuable to take the AXL1717 clinical development project forward” said Ulrika Wennberg, CEO.
About AXL1717 (picropodophyllin)
AXL1717 is an orally bioavailable small molecule with dual mechanisms of action, which has been shown to pass through the blood-brain barrier. AXL1717 targets the IGF-1R signaling pathway but does not bind the IGF-1R. AXL1717 has also been shown to yield cell cycle arrest in mitosis, due to indirect effects on microtubule dynamics, making it a unique anti-cancer drug.
About Axelar AB
Axelar is a Swedish drug development company developing targeted oral anti-cancer therapies for indications where there are significant unmet medical needs. The company was founded based on research performed at Karolinska Institutet, Stockholm and the discovery of a group of compounds that target the IGF-1 receptor signaling pathway without affecting signaling from the closely related insulin receptor.
For additional information about Axelar, please visit www.axelar.se